Taking enzalutamide improves overall survival and progression-free survival in men with hormone-sensitive metastatic prostate cancer compared with standard antiandrogen therapies, report Australian researchers.

The first interim results of the ENZAMET trial show that men on enzalutamide are 33% less likely to have died than men on standard therapy after a median of 34 months’ follow-up.

Overall survival at three years was 80% in the enzalutamide group and 72% in the standard care group.

Results were even better for progression-free survival, with men in the enzalutamide arm about 60% less likely to have progression — whether measured radiographically or by a rise in PSA — the authors reported in the New England Journal of Medicine.